Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
Financial Figures/Balance Sheet
- Turnover extended by 4.4% to 210.4 million Euro in financial year 2005/2006 - Company annual surplus increases by 3.4 million Euro to 9.7 million Euro - Capital ratio rises clearly

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

20.10.2006

Berlin, 20th October 2006. The Marseille-Kliniken AG, (Prime Standard, ISIN DE 0007783003, MKA) is continuing to grow and is recording above-average results. In the financial year of 2005/06 the company’s turnover increased to 210.4 million Euro (previous year: 201.5 million Euro). The EBIT result according to IFRS improved from 23.1 million Euro in the previous year to 25.8 million Euro in the year under review. The company’s annual surplus improved from 6.3 million Euro to 9.7 million Euro. The DVFA/SG (IFRS) adjusted result was 9.3 million Euro in the financial year compared to 8.9 million Euro the previous year. Per share this is equal to a result increase of 0.03 Euro to 0.76 Euro (previous year: 0.73 Euro). The equity capital recorded on the balance sheet is 66.8 million Euro as against 62.6 million Euro in the previous year, which equates to a capital ratio of 20.7% (previous year 15.5%).

The care sector is still the growth driver for turnover and results, in which the bed capacity was expanded by 1233 beds to 7134 beds during the financial year (previous year: 5901 beds). Within the company the entire capacity therefore increased to 8703 beds. With a turnover of 162.7 million Euro, the Marseille-Kliniken AG achieved a growth of 11.7 million Euro in the care sector, compared to 151.0 million Euro in the previous year. At 12.9 million Euro the result according to DVFA/SG (IFRS) exceeded the previous year’s value of 12.5 million Euro  by 0.4 million Euro. The occupancy rate was also improved, despite the current negative start-up effects from the new facilities and with 91.6% exceeded the previous year’s figure of 90.7%. Therefore in total the company occupancy rate with 88.2% was above the level of the previous year of 87.5%.

The rehabilitation sector has been further improved. Through the closure of two facilities and the purchase of a gerontological specialist clinic in Büren, the total number of facilities decreased to 10 (previous year: 11). Therefore, according to plan the bed capacity in this sector decreased by 103 beds to 1569 beds (previous year: 1672 beds). The occupancy rate for the entire year was primarily influenced by the unexpectedly poor third quarter and the doctor’s strike and decreased from 76.6% in the previous year to 74.2% over the entire year. In the rehabilitation sector the turnover has been reduced from 50.5 million Euro in the previous year to 47.7 million Euro in the year under review. With -3.6 million Euro the DVFA/SG adjusted result (IFRS) remained at the level of the previous year. The restructuring measures in this sector are consistently being taken and form the basis for a lasting turnaround, so that the board of directors is counting on positive effects in this sector in the short to medium term.

End of the ad hoc release

@@start.t2@@end of announcement                                                 euro adhoc 20.10.2006 07:55:22
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
If you have any questions please contact:

Marseille-Kliniken AG   Hillermann Consulting
Axel Hölzer                 Christian Hillermann
CEO                             Investor Relations
Alte Jakobstraße 79/80   Eppendorfer Baum 5
10709 Berlin                 20249 Hamburg
Tel.: 030 / 246 32-400   Tel.: 040 / 414 069-13
Fax: 030 / 246 32-401   Fax: 040 / 414 069-14

Branche: Pharmaceuticals
ISIN:      DE0007783003
WKN:        778300
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurter Wertpapierbörse / official dealing/prime standard
              Börse Berlin-Bremen / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Hamburger Wertpapierbörse / official dealing



Das könnte Sie auch interessieren: